BIOMAT Database Logo BIOMAT Database Logo

Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers. 1998

D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.

OBJECTIVE To assess the effect of ranitidine on the pharmacokinetics of eprosartan in healthy male volunteers. METHODS Single-center, randomized, open-label, two-period, period-balanced, crossover study. METHODS Seventeen healthy men aged 19 to 43 years. METHODS In each period (separated by a > or = 7 d washout), subjects received a single 400-mg oral dose of eprosartan alone, or a single oral dose of eprosartan 400 mg and ranitidine 150 mg on day 4 after 3 days of ranitidine 150 mg twice daily. Serial pharmacokinetic samples were obtained for up to 24 hours following eprosartan dosing. METHODS Plasma and urine eprosartan concentrations during each treatment session. RESULTS Eprosartan maximum concentration (Cmax), the AUC from time-zero to the last quantifiable concentration (AUC0-t), and renal clearance (Cl(r)) values were approximately 7%, 11%, and 4% lower, respectively, when administered with ranitidine compared with eprosartan alone. The 95% CIs for the ratio of eprosartan plus ranitidine compared with eprosartan alone were 0.81 to 1.07, 0.77 to 1.03, and 0.64 to 1.43, for Cmax, AUC0-t, and Cl(r), respectively, indicating no statistically significant difference between regimens. CONCLUSIONS Repeated doses of ranitidine did not have a marked effect on the single-dose pharmacokinetics of eprosartan.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000179 Acrylates Derivatives of acrylic acid (the structural formula CH2
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
Pharmacokinetics of glycerol administered orally in healthy volunteers.
July 1993, Arzneimittel-Forschung,
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
Pharmacokinetics of orally administered tizanidine in healthy volunteers.
January 1987, Fundamental & clinical pharmacology,
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
July 2002, Clinical therapeutics,
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
The pharmacokinetics of orally administered fudosteine in healthy Chinese volunteers.
January 2006, European journal of drug metabolism and pharmacokinetics,
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
Eprosartan mesylate, an angiotensin II receptor antagonist.
April 2011, Acta crystallographica. Section E, Structure reports online,
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
August 1997, Hypertension (Dallas, Tex. : 1979),
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers].
March 1986, Giornale italiano di cardiologia,
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
Effects of orally administered activated charcoal on ciprofloxacin pharmacokinetics in healthy volunteers.
December 1988, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
July 2000, Hypertension (Dallas, Tex. : 1979),
D M Tenero, and D E Martin, and B E Ilson, and D A Boyle, and S C Boike, and A M Carr, and D E Lundberg, and D K Jorkasky
Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients.
January 2003, Drug metabolism and pharmacokinetics,
Copied contents to your clipboard!